 Zacks Investment Research lowered shares of Armata Pharmaceuticals NYSEAMERICAN:ARMP from a buy rating to a hold rating in a research report sent to investors on Friday morning, Zacks.com reports. According to Zacks, Armata Pharmaceuticals Inc. is a biotechnology company. It is focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based ... 